Kura Oncology (KURA) Misses Q2 EPS by 34c

Kura Oncology (NASDAQ: KURA) reported Q2 EPS of ($0.75), $0.34 worse than the analyst estimate of ($0.41). Revenue for the quarter came in at $15.3 million versus the consensus estimate of $39.11 million.

For earnings history and earnings-related data on Kura Oncology (KURA) click here.

You May Also Be Interested In

• Citi raises Atlassian price target to $225, maintains Buy rating
• Citi raises Wendy's price target to $8.25, keeps neutral rating
• Citi Opens 30-Day Upside Catalyst Watch on Howmet Aerospace Inc. (HWM)